The PGY2 Oncology Residency at Nebraska Medicine offers a unique and stimulating learning environment, which provides comprehensive clinical training in hematology and oncology pharmacy practice. The goal of the residency program is to develop clinical practitioners who specialize in the care of oncology patients and have an interest in education and research. After orientation, residents will participate in ten months of clinical rotations in addition to longitudinal experiences in our outpatient infusion center, teaching, and clinical research.
Nebraska Medicine is a nationally respected cancer center and one of the founding members of the National Comprehensive Cancer Network (NCCN). PGY2 Oncology pharmacy residents at Nebraska Medicine will have the opportunity to work on the forefront of cancer treatments with nationally recognized practitioners. The resident will be integrally involved with health-care professionals throughout the continuum of patient care, including patient education, assessment, and therapeutic recommendations. Working with experienced pharmacy clinicians, the PGY2 pharmacy resident also will gain experience serving as a preceptor for pharmacy students and PGY1 pharmacy residents. Residents will provide compassionate, evidence-based, progressive medical care in both inpatient and outpatient settings. The program allows tailored instruction for the individual based on interest and past experiences.
PGY2 residents are required to fulfill the service commitment (staffing) designed to ensure that residents gain experience and can function as competent clinical oncology practitioners. Each resident will train with preceptors and basic training will take place during the first month of residency. At the conclusion of the basic training period, the designated preceptors and the resident will mutually determine if the resident is ready to function independently as a pharmacist.
As part of the service commitment for PGY2 residents, the following staffing requirements apply:
- PGY2 residents will staff 22 shifts throughout the year, approximately two shifts per month that may or may not include weekends and/or evenings.
- PGY2 residents must work one holiday.
- Staffing will occur on the Werner Oncology/Hematology Special Care Unit.
- Orientation (July)
- Adult Stem Cell Transplant
- Medical Oncology/Hematology
- Pediatric Hematology/Oncology
- Oncology Pharmacy Management
- Infusion Center
- Gynecology Oncology Inpatient/Clinic
- Ambulatory Clinic (Solid Tumors and Hematologic Malignancies)
- Specialty Pharmacy
- Oncology Infectious Diseases
- Oncology Infectious Disease
- Pain Management/Palliative Care
- Disease Specific Ambulatory Clinic
- Transitions of Care
- Benign Hematology
- Investigational Drug Service
- Critical Care – Werner ICU
- Drug Policy/Formulary Management
- Oncology Residency Conference/Teaching
- Pharmacy Grand Rounds
- Investigational Drug Service
- Weekly Ambulatory Clinic (Solid Tumors and Hematologic Malignancies)
Nebraska Medicine is the clinical partner of the University of Nebraska Medical Center (UNMC), which includes the Colleges of Medicine, Pharmacy, Nursing, Dentistry and Allied Health. UNMC is the only public academic health science center in Nebraska and is internationally recognized as a leader in patient care, research and education. With a history dating to 1869, the 809-bed not-for-profit hospital is known for excellence and innovation in medicine. Nebraska Medicine brings together the expertise of private practice medicine with the strengths of an academic health center. As the primary teaching hospital for UNMC, Nebraska Medicine is a respected leader in solid organ transplantation, cardiology, general oncology, radiation oncology, blood and marrow transplantation, neonatology, and neurology. By combining state-of-the-art research, education and extraordinary patient care, we offer the best of both worlds.
The Fred and Pamela Buffett Cancer Center, an entity of Nebraska Medicine and UNMC, integrates research and education with patient care to offer the most up-to-date treatments for a variety of cancers. This unique collaboration between Nebraska Medicine cancer physicians and UNMC researchers allows discoveries made in the laboratories to be taken directly to the patient.
The blood and marrow transplantation program has been recognized internationally for pioneering autologous transplantation for lymphoma, using peripheral stem cells as an alternative rescue product, conducting groundbreaking studies on various growth factors and performing transplants in alternate settings other than traditional inpatient hospital units. The outpatient transplant program employs a care model that allows patients and their care partners to play an active role in the treatment and recovery process following cancer care. Our health-care providers understand that each patient is unique and uses a team approach to develop a specialized plan of care for each patient to optimize outcomes.
Jared Matya, PharmD, BCOP
Clinical Pharmacist Practitioner – Blood and Marrow Transplant
PGY2 Oncology Residency Program Director
981090 Nebraska Medical Center
Omaha, NE 68198-1090
Email Jared Matya